Additional file 3: of Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial

SUN☺D Investigators and committee members. (DOCX 17 kb

Additional file 2: of Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial

Figure S1. Schedule of the assessments. Table S1. Incidence of suicidality, manic switches or any serious adverse events up to week 9 for step 1 randomisation. Table S2. Incidence of suicidality, manic switches or any serious adverse events up to week 25 for step 1 randomisation. Table S3. Two pre-specified subgroup analyses for step 1 randomisation. Table S4. Four pre-specified sensitivity analyses for step 1 randomisation. Table S5. Incidence of suicidality, manic switches or any serious adverse events up to week 9 for step 2 randomisation. Table S6. Incidence of suicidality, manic switches or any serious adverse events up to week 25 for step 2 randomisation. Table S7. Three pre-specified subgroup analyses for step 2 randomisation. (DOCX 32 kb

Additional file 1: of Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial

Blinded data analyses statement of interpretation. (PDF 336 kb